LncRNA-CASC7 and lncRNA H19 upregulate the expression of PTEN by directly targeting miR-21 to inhibit the PI3K/Akt pathway, whereas downregulation of lncRNA-CASC7 and lncRNA H19 was observed in ASMCs from patients with severe asthma, suggesting that both these lncRNAs could be potential targets in the treatment of asthma [46, 47]. Here, AGO2 is linked to asthma.